Akoya Biosciences, INC Form 4 insider transactions

Akoya Biosciences' CEO, Brian McKelligon, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Akoya Biosciences CEO Brian McKelligon exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Akoya Biosciences' CEO, Brian McKelligon, sold 7,500 shares of common stock at an average price of $4.938 per share on March 13, 2024, under a pre-arranged trading plan.

Director Robert G. Shepler reports gifting shares of Akoya Biosciences to separate property and gift trusts.

Brian McKelligon, CEO of Akoya Biosciences, reports acquisition of restricted stock units and stock options, as well as a disposition of shares to cover taxes.

CFO John Frederick Ek reports acquisition of 35,000 shares of common stock and 70,000 employee stock options in Akoya Biosciences.

Jennifer Kamocsay, General Counsel of Akoya Biosciences, reports the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover taxes.

Frederic Pla, COO of Akoya Biosciences, reports acquisition of shares and stock options, as well as shares withheld for taxes.

Niro Ramachandran, Chief Business Officer of Akoya Biosciences, acquired stock options and restricted stock units, and had shares withheld for taxes.

Brian McKelligon, CEO of Akoya Biosciences, reports the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover taxes.